← 返回

胃癌免疫治疗的机制、进展与挑战

英文原题:Mechanisms, advances, and challenges of immunotherapy in gastric cancer.

查看英文原题

Mechanisms, advances, and challenges of immunotherapy in gastric cancer.

PubMed 2025/09/04(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胃癌是全球范围内最常见的消化道恶性肿瘤之一,其特点是发病率高、筛查率低、早期症状隐匿,因此多数患者确诊时已处于晚期或转移阶段,总体预后较差。近年来,免疫治疗的兴起和不断发展改变了胃癌传统的治疗格局,为精准医疗带来了新的希望。免疫治疗主要通过调节免疫抑制性肿瘤微环境发挥抗肿瘤作用,包括免疫检查点抑制剂(ICIs)、过继性细胞疗法(ACT)和肿瘤疫苗等模式。其中,ICIs和ACT受到了广泛关注。本文综述了胃癌免疫治疗的基本机制、当前应用及主要挑战。此外,我们还讨论了具有潜在效用的新兴生物标志物,用于预测胃癌患者的免疫治疗疗效。

展开英文摘要原文

Gastric cancer (GC) is one of the most common gastrointestinal malignancies worldwide, characterized by a high incidence rate, low screening rate, and subtle early symptoms. As a result, the majority of patients are diagnosed at an advanced or metastatic stage, contributing to poor overall prognosis. In recent years, the emergence and continuous advancement of immunotherapy have revolutionized the traditional treatment landscape for GC, offering new hope for precision medicine.

Immunotherapy exerts its antitumor effects primarily by modulating the immunosuppressive tumor microenvironment and includes modalities such as immune checkpoint inhibitors (ICIs), adoptive cell therapies (ACTs), and cancer vaccines. Among these, ICIs and ACT have garnered significant attention. This review summarizes the underlying mechanisms, current applications, and major challenges of immunotherapy in GC.

In addition, we discuss emerging biomarkers with potential utility for predicting immunotherapeutic efficacy in GC patients.

论文信息

作者
Wang Z、Wang T
第一作者单位
College of Basic Medical Sciences, Naval Medical University, Shanghai, China.China
通讯作者单位
Research Center of Translational Medicine, Naval Medical University, Shanghai, China.China
文献类型
综述
期刊
Frontiers in immunology2025
原文标识
PubMed 40977703 · DOI 10.3389/fimmu.2025.1639487